David James Lennon sold $93k of WHWK
CHIEF EXECUTIVE OFFICER at Aadi Bioscience, Inc.. 26,858 shares at an average of $3.48, traded Apr 2, 2026, filed Apr 3, 2026.
Score components
- +25RoleCEO
- +10Trade size$93k at market
- 0Share of holdings soldSold 3.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001995275-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | MOption exercise Common Stock | +775,828 | - | - | 820,407 | Apr 3, 2026 |
| Apr 2, 2026 | SOpen-market sale Common Stock | -26,858 | $3.48 | $93k | 793,549 | Apr 3, 2026 |
| Apr 1, 2026 | MOption exercise Restricted Stock Unitsderivative | -775,828 | $0.00 | $0 | 0 | Apr 3, 2026 |
| Apr 1, 2026 | AGrant or award Stock Option (right to buy)derivative | +831,148 | $0.00 | $0 | 831,148 | Apr 3, 2026 |
Related signals
Other insiders at Aadi Bioscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 70Notable | Aadi Bioscience, Inc. | Scott M. Giacobello CHIEF FINANCIAL OFFICER | $882k 218,600 shares | -43% | |
| 52Moderate | Aadi Bioscience, Inc. | Bryan Ball See remarks | $428k 118,849 shares | -23% | |
| 42Moderate | Aadi Bioscience, Inc. | Bryan Ball See remarks | $201k 56,596 shares | -10% | |
| 47Moderate | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $49k 14,500 shares | -3% | |
| 74Notable | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $900k 260,427 shares | -33% | |
| 15Weak | Aadi Bioscience, Inc. | Bryan Ball See remarks | $6,070 1,834 shares | -1% | |
| 22Weak | Aadi Bioscience, Inc. | Scott M. Giacobello CHIEF FINANCIAL OFFICER | $8,585 2,594 shares | -8% | |
| 30Weak | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $17k 5,100 shares | -10% | |
| 15Weak | Aadi Bioscience, Inc. | Bryan Ball See remarks | $5,045 2,147 shares | -2% | |
| 30Weak | Aadi Bioscience, Inc. | David James Lennon CHIEF EXECUTIVE OFFICER | $13k 5,690 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.